These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 33207029)

  • 1. Assessment of treatment options for patients with hepatitis C virus recombinant form 2k/1b.
    Zakalashvili M; Zarkua J; Gish RG; Zhamutashvili M; Sartania V; Weizenegger M; Bartel J; Raabe M; Gvinjilia L; Metreveli S; Barnova M; Abramishvili N; Rtskhiladze I; Metreveli D
    Hepatol Res; 2021 Feb; 51(2):156-165. PubMed ID: 33207029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of hepatitis C virus recombinant form RF1_2k/1b on treatment outcomes within the Georgian national hepatitis C elimination program.
    Karchava M; Chkhartishvili N; Sharvadze L; Abutidze A; Dvali N; Gatserelia L; Dzigua L; Bolokadze N; Dolmazashvili E; Kotorashvili A; Imnadze P; Gamkrelidze A; Tsertsvadze T
    Hepatol Res; 2018 Jan; 48(1):36-44. PubMed ID: 28258606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience.
    Mangia A; Susser S; Piazzolla V; Agostinacchio E; De Stefano G; Palmieri V; Spinzi G; Carraturo I; Potenza D; Losappio R; Arleo A; Miscio M; Santoro R; Sarrazin C; Copetti M
    J Hepatol; 2017 Apr; 66(4):711-717. PubMed ID: 27965158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of hepatitis C virus 2k/1b intergenotypic recombinants in Georgia.
    Zakalashvili M; Zarkua J; Weizenegger M; Bartel J; Raabe M; Zangurashvili L; Kankia N; Jashiashvili N; Lomidze M; Telia T; Kerashvili V; Zhamutashvili M; Abramishvili N; Hedskog C; Chodavarapu K; Brainard DM; McHutchison JG; Mo H; Svarovskaia E; Gish RG; Rtskhiladze I; Metreveli D
    Liver Int; 2018 Mar; 38(3):451-457. PubMed ID: 28782185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras.
    Susser S; Dietz J; Schlevogt B; Zuckerman E; Barak M; Piazzolla V; Howe A; Hinrichsen H; Passmann S; Daniel R; Cornberg M; Mangia A; Zeuzem S; Sarrazin C
    J Hepatol; 2017 Oct; 67(4):680-686. PubMed ID: 28619439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
    Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
    BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence of Hepatitis C Virus Genotype Recombinant Forms 2k/1b in Georgia.
    Zakalashvili M; Weizenegger M; Bartel J; Markowski M; Zarqua J; Kavsadze S; Kvatadze K; Basheleishvili G; Phirtskhalaishvili T; Dzagania T; Zangurashvili L; Kankia N; Jashiashvili N; Lomidze M; Telia T; Kerashvili V; Zhamutashvili M; Abramishvili N; Rtskhiladze I; Metreveli D
    Clin Lab; 2016 Jul; 62(7):1347-1351. PubMed ID: 28164650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heads or Tails: Genotyping of Hepatitis C Virus Concerning the 2k/1b Circulating Recombinant Form.
    Schuermans W; Orlent H; Desombere I; Descheemaeker P; Van Vlierberghe H; Geerts A; Verhelst X; Reynders M; Padalko E
    Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27563879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
    Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
    J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
    Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
    J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.
    Younossi ZM; Stepanova M; Sulkowski M; Foster GR; Reau N; Mangia A; Patel K; Bräu N; Roberts SK; Afdhal N; Nader F; Henry L; Hunt S
    Clin Infect Dis; 2016 Oct; 63(8):1042-1048. PubMed ID: 27444413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful Hepatitis C Virus Eradication in a Hemodialysis Patient With 2k/1b Chimera Genotype: A Case Report and Literature Review.
    Zubkin ML; Shchepetkova GS; Balkarova OV; Chervinko VI; Kryukov EV
    Gastroenterology Res; 2019 Jun; 12(3):176-180. PubMed ID: 31236161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology and Genotype Distribution of Hepatitis C Virus in Russia.
    Pimenov N; Kostyushev D; Komarova S; Fomicheva A; Urtikov A; Belaia O; Umbetova K; Darvina O; Tsapkova N; Chulanov V
    Pathogens; 2022 Dec; 11(12):. PubMed ID: 36558817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan.
    Igarashi A; Tang W; Guerra I; Marié L; Cure S; Lopresti M
    Curr Med Res Opin; 2017 Jan; 33(1):11-21. PubMed ID: 27609424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
    Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
    PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.
    Butt AA; Yan P; Shaikh OS; Chung RT; Sherman KE;
    Liver Int; 2016 Sep; 36(9):1275-83. PubMed ID: 26928927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
    Moser S; Kozbial K; Laferl H; Schütz A; Reiberger T; Schwabl P; Gutic E; Schwanke C; Schubert R; Luhn J; Lang T; Schleicher M; Steindl-Munda P; Haltmayer H; Ferenci P; Gschwantler M
    Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):291-295. PubMed ID: 29120906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials.
    Yang YM; Choi EJ
    Ther Clin Risk Manag; 2017; 13():477-497. PubMed ID: 28442915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection.
    Younossi ZM; Stepanova M; Henry L; Han KH; Ahn SH; Lim YS; Chuang WL; Kao JH; Nguyen KV; Lai CL; Chan HL; Wei L
    J Viral Hepat; 2018 Dec; 25(12):1429-1437. PubMed ID: 29974665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir.
    Nguyen E; Trinh S; Trinh H; Nguyen H; Nguyen K; Do A; Levitt B; Do S; Nguyen M; Purohit T; Shieh E; Nguyen MH
    Aliment Pharmacol Ther; 2019 Jan; 49(1):99-106. PubMed ID: 30467877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.